ABL and Coave Therapeutics enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy
AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II
Nosopharm signs partnership with INRAE and University of Montpellier to develop new anti-infectives
Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
Tollys and Gustave Roussy enter into new research agreement
Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer
Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting
